Effects of recombinant bovine interleukin-8 (rbIL-8) treatment on health, metabolism, and lactation performance in Holstein cattle IV: Insulin resistance, dry matter intake, and blood parameters

Immune and metabolic effects of rumen-protected methionine during a heat stress challenge in lactating Holstein cows

Multiparous, lactating Holstein cows (n = 32) were randomly assigned to one of two dietary treatments [TMR with rumen-protected Met (RPM) or TMR without RPM (CON)], and within each dietary treatment group cows were randomly assigned to one of two environmental treatment groups in a split-plot crossover design. In phase 1 (9 d), all cows were fed ad libitum and in thermoneutral conditions (TN). In phase 2 (9 d), group 1 (n = 16) was exposed to a heat stress (HS) challenge (HSC). Group 2 cows (n = 16) were pair-fed (PFTN) to HSC counterparts and remained in TN. After a 21-d washout period, the study was repeated (period 2) and the environmental treatments were inverted relative to treatments from phase 2 of period 1, while dietary treatments remained the same for each cow. During phase 1, cows in RPM had greater plasma Met concentration compared with cows in CON (59 and 30 µM, respectively; P < 0.001). Cows in PFTN had a greater decrease (P < 0.05) in plasma insulin than cows in HSC at 4 h (-2.7 µIU/mL vs. -0.7 µIU/mL) and 8 h (-7.7 µIU/mL vs. -0.4 µIU/mL) during phase 2. Compared with cows in PFTN, cows in HSC had an increase (P < 0.05) in plasma serum amyloid A (-59 µg/mL vs. +58 µg/mL), serum haptoglobin (-3 µg/mL vs. +33 µg/mL), plasma lipopolysaccharide binding protein (-0.27 and +0.11 µg/mL), and plasma interleukin-1β (-1.9 and +3.9 pg/mL) during phase 2. In conclusion, HSC elicited immunometabolic alterations; however, there were limited effects of RPM on cows in HSC.

Elevated serotonin alters whole-blood expression of serotonin receptor and metabolism genes in the lactating dairy cow

Serotonin's role as a hormone has been demonstrated through modulating calcium metabolism, energy homeostasis, and immune function in the preweaned and lactating bovine. Recently, manipulation of the serotonergic axis in calves via administration of 5-hydroxy-l-tryptophan (5-HTP), the serotonin precursor, elicited immunomodulatory effects and regulated serotonin transport and metabolism genes in leukocytes. However, serotonin's ability to modulate whole-blood gene expression in lactating dairy cows is unknown. Our objective was to explore the effect of infusing 5-HTP on whole-blood expression of genes regulating serotonin transport (reuptake transporter), signaling (receptors), metabolism (synthesis and degradation), and cytokines in dairy cows. Twelve lactating multiparous Holstein dairy cows were blocked by parity, milk production, and days in milk in a randomized complete block design and randomly assigned to intravenous infusion of either 1 L of 1.5 mg/kg 5-HTP dissolved in saline (n = 6) or 1 L of saline solution (n = 6) for 3 consecutive days. Whole blood was collected at 48, 56, and 72 h relative to termination of first infusion to analyze whole-blood gene expression. Infusion of 5-HTP increased whole-blood mRNA expression of monoamine oxidase-A and serotonin receptor 7 across the experimental period. Forty-eight hours from termination of first infusion, the mRNA of monoamine oxidase-A, serotonin reuptake transporter, and serotonin receptor 7 were increased in blood relative to the control. Interleukin-8 concentrations and mRNA were unchanged in response to 5-HTP infusion. Collectively, these data suggest that infusion of 5-HTP may alter mRNA of serotonin metabolism, transport, and signaling genes in whole blood of lactating dairy cows.

Metabolic alterations in dairy cows with subclinical ketosis after treatment with carboxymethyl chitosan-loaded, reduced glutathione nanoparticles

Background

Subclinical ketosis (SCK) causes economic losses in the dairy industry because it reduces the milk production and reproductive performance of cows.

Hypothesis/Objectives

To evaluate whether carboxymethyl chitosan‐loaded reduced glutathione (CMC‐rGSH) nanoparticles can alleviate the incidence or degree of SCK in a herd.

Animals

Holstein dairy cows 21 days postpartum (n = 15).

Methods

The trial uses a prospective study. Five cows with serum β‐hydroxybutyric acid (BHBA) ≥1.20 mmol/L and aspartate aminotransferase (AST) <100 IU/L were assigned to group T1, 5 cows with BHBA ≥1.20 mmol/L and AST >100 IU/L to group T2, and 5 cows with BHBA <1.00 mmol/L and AST <100 IU/L to group C. Carboxymethyl chitosan‐loaded reduced glutathione (0.012 mg/kg body weight per cow) was administered to cows in T1 and T2 once daily via jugular vein for 6 days after diagnosis. Serum from all groups were collected 1 day before administration, then on days 1, 3, 5, 7, 10, and 15 after administration to determine the changes in biochemical index and ¹H‐NMR.

Results

The difference in liver function or energy metabolism indices in T1, T2, and C disappeared at day 7 and day 10 after the administration (P > .05). Valine, lactate, alanine, lysine, creatinine, glucose, tyrosine, phenylalanine, formate, and oxalacetic acid levels, and decrease in isoleucine, leucine, proline, acetate, trimethylamine N‐oxide, glycine, and BHBA levels were greater (P < .05) at day 7 than day 0 for cows in T2.

Conclusions and Clinical Importance

Carboxymethyl chitosan‐loaded reduced glutathione treatment might alleviate SCK by enhancing gluconeogenesis and reducing ketogenesis in amino acids.

Recent advances and future directions for uterine diseases diagnosis, pathogenesis, and management in dairy cows

Researchers, veterinarians, and farmers' pursuit of a consistent diagnosis, treatment, and prevention of uterine diseases remains challenging. The diagnosis and treatment of metritis is inconsistent, a concerning situation when considered the global threat of antimicrobial resistance dissemination. Endometritis is an insidious disease absent on routine health programs in many dairy farms and from pharmaceutical therapeutics arsenal in places like the US market. Conversely, a multitude of studies advanced the understanding of how uterine diseases compromise oocyte, follicle, and embryo development, and the uterine environment having long-lasting effects on fertility. The field of uterine disease microbiome also experienced tremendous progress and created opportunities for the development of novel preventives to improve the management of uterine diseases. Activity monitors, biomarkers, genomic selection, and machine learning predictive models are other innovative developments that have been explored in recent years to help mitigate the negative impacts of uterine diseases. Albeit novel tools such as vaccines for metritis, immune modulators, probiotics, genomic selection, and selective antimicrobial therapy are promising, further research is warranted to implement these technologies in a systematic and cost-effective manner.